FDA EDWARDS COMMITTEE HAS NEW MEMBER, WARNER-LAMBERT CHAIRMAN
FDA EDWARDS COMMITTEE HAS NEW MEMBER, WARNER-LAMBERT CHAIRMAN Joseph Williams, chosen to succeed Syntex President Paul Freiman. Williams will join the Edwards Committee in time for its next meeting on July 11-12. Freiman resigned from the committee prior to its first meeting in May in the wake of concern about his appointment expressed by Sen. Metzenbaum (D-Ohio). Chaired by Scripps Clinic President Charles Edwards, MD, the committee, also known as the "blue ribbon" panel, was formed to develop recommendations on how to strengthen FDA. Williams will be assigned to the committee's Subcommittee on Drugs and Biologics, chaired by David Kessler, MD, medical director, Albert Einstein College of Medicine ("The Pink Sheet" May 21, p. 3). Other members of the subcommittee include: Sen. Kennedy's (D-Mass.) former health aide Lawrence Horowitz, MD, now with James D. Wolfensohn, Inc.; Louis Lasagna, MD, Sackler School of Graduate Biomedical Sciences; former American Medical Association President Alan Nelson, MD; and Mylan President Milan Puskar. Williams has extensive experience in Washington committees. He was chairman of the Pharmaceutical Manufacturers Association during the acrimonious debate over the Waxman-Hatch ANDA/patent restoration act in 1984. His career spans 40 years in the pharmaceutical industry. Currently chairman of Project Hope, he is also a past president of the International Federation of Pharmaceutical Manufacturers Association (1986-1988).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth